

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/254376 A1

(51) International Patent Classification:

A01K 67/0275 (2024.01) C12N 15/86 (2006.01)
C07K 14/47 (2006.01)

(21) International Application Number:

PCT/US2024/032909

(22) International Filing Date:

07 June 2024 (07.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/506,872 08 June 2023 (08.06.2023) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **HUANG, Brian**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **GAO, Min**; c/o Regeneron Pharmaceu-

ticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **DUGAN, John**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **SCHILLING, Stephen H.** et al.; Alston & Bird LLP, Vantage South End, 1120 South Tryon Street, Suite 300, Charlotte, North Carolina 28203-6818 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: ANIMAL MODEL WITH RAPID ONSET OF ALZHEIMER'S AMYLOID BETA PLAQUE PATHOLOGY

AAV9-hSyn-hAPP695 (KM595/596NL+E618G+I641F)
AAV9-hSyn-PSEN1 (M146L+L286V)




FIG. 1

(57) Abstract: Provided herein are compositions comprising a nucleic acid encoding amyloid-beta precursor protein and/or a nucleic acid encoding presenilin-1, cells comprising the compositions, animals comprising the compositions, methods of making the cells and animals, methods of modeling Alzheimer's disease, methods of assessing a therapeutic candidate for the treatment of Alzheimer's disease or amelioration of a symptom or phenotype of Alzheimer's disease, and methods of assessing a therapeutic candidate for the prevention of Alzheimer's disease or prevention of a symptom or phenotype of Alzheimer's disease.

[Continued on next page]



WO 2024/254376 A1

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*